Comparative Pharmacology
Head-to-head clinical analysis: LEUPROLIDE ACETATE versus SUPPRELIN LA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: LEUPROLIDE ACETATE versus SUPPRELIN LA.
LEUPROLIDE ACETATE vs SUPPRELIN LA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Leuprolide acetate is a synthetic gonadotropin-releasing hormone (GnRH) agonist. Upon continuous administration, it suppresses pituitary gonadotropin secretion by downregulating GnRH receptors, leading to decreased luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels, and consequently reducing sex steroid (testosterone and estrogen) production in the gonads.
SUPPRELIN LA is a sterile, biodegradable, subcutaneous implant containing histrelin acetate, a synthetic nonapeptide agonist of gonadotropin-releasing hormone (GnRH). After an initial transient increase, continuous administration results in downregulation of pituitary GnRH receptors, leading to suppressed luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion, thereby reducing gonadal sex steroid production (testosterone in males, estradiol in females) to castrate levels.
Prostate cancer: 7.5 mg IM once monthly or 22.5 mg IM once every 3 months or 45 mg SC once every 6 months. Central precocious puberty: 50 mcg/kg/day SC or 7.5 mg IM once monthly. Endometriosis: 3.75 mg IM once monthly or 11.25 mg IM once every 3 months.
50 mg subcutaneously once every 12 months (implant placed in inner upper arm).
None Documented
None Documented
Terminal elimination half-life is approximately 3 hours following intravenous administration; after subcutaneous depot formulations, the effective half-life is extended due to slow release, with a terminal half-life of about 3-4 weeks for the 1-month depot.
Terminal half-life approximately 3-4 hours; clinical suppression of luteinizing hormone and testosterone sustained for 4 weeks due to depot formulation.
Renal: approximately 5% as unchanged drug; hepatic metabolism accounts for the majority of clearance, with metabolites excreted renally and fecally; biliary excretion is minimal.
Renal: <5% unchanged; hepatic metabolism; fecal elimination of metabolites.
Category D/X
Category C
GnRH Agonist
GnRH Agonist